Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
165 results
Cited 9 times since 2013 (0.8 per year) source: EuropePMC
European journal of preventive cardiology, Volume 20, Issue 2 Suppl, 1 1 2013, Pages 8-12 Remote monitoring of patients with implanted devices: data exchange and integration. Van der Velde ET, Atsma DE, Foeken H, Witteman TA, Hoekstra WH
Background: Remote follow-up of implanted implantable cardioverter defibrillators (ICDs) may offer a solution to the problem of overcrowded outpatient clinics, and may also be effective in detecting clinical events early. Data obtained from remote follow up systems, as developed by all major device companies, are stored in a central database system, operated and owned by the device company. A problem now arises that the patient's clinical information is partly stored in the local electronic... Abstract
Cited 7 times since 2013 (0.6 per year) source: EuropePMC
International journal of cardiology, Volume 168, Issue 3, 26 4 2013, Pages 3031-3032 Long term effects of intramyocardial bone marrow cell injection on anginal symptoms and quality of life in patients with chronic myocardial ischemia. van Ramshorst J, Rodrigo SF, Beeres SL, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Atsma DE
Cited 25 times since 2013 (2.2 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 6, Issue 2, 18 3 2013, Pages 380-391 Engraftment patterns of human adult mesenchymal stem cells expose electrotonic and paracrine proarrhythmic mechanisms in myocardial cell cultures. Askar SF, Ramkisoensing AA, Atsma DE, Schalij MJ, de Vries AA, Pijnappels DA
Background: After intramyocardial injection, mesenchymal stem cells (MSCs) may engraft and influence host myocardium. However, engraftment rate and pattern of distribution are difficult to control in vivo, hampering assessment of potential adverse effects. In this study, the role of the engraftment patterns of MSCs on arrhythmicity in controllable in vitro models is investigated. Methods and results: Cocultures of 4×10(5) neonatal rat cardiomyocytes and 7% or 28% adult human MSCs (hMSCs) in diff... Abstract
Cited 20 times since 2013 (1.8 per year) source: EuropePMC
Differentiation; research in biological diversity, Volume 85, Issue 3, 1 1 2013, Pages 101-109 Polycistronic lentivirus induced pluripotent stem cells from skin biopsies after long term storage, blood outgrowth endothelial cells and cells from milk teeth. Dambrot C, van de Pas S, van Zijl L, Brändl B, Wang JW, Schalij MJ, Hoeben RC, Atsma DE, Mikkers HM, Mummery CL, Freund C
The generation of human induced pluripotent stem cells (hiPSCs) requires the collection of donor tissue, but clinical circumstances in which the interests of patients have highest priority may compromise the quality and availability of cells that are eventually used for reprogramming. Here we compared (i) skin biopsies stored in standard physiological salt solution for up to two weeks (ii) blood outgrowth endothelial cells (BOECs) isolated from fresh peripheral blood and (iii) children's mi... Abstract
Cited 3 times since 2012 (0.3 per year) source: EuropePMC
Stem cells (Dayton, Ohio), Volume 30, Issue 12, 1 1 2012, Pages 2830-2834 Brief report: Misinterpretation of coculture differentiation experiments by unintended labeling of cardiomyocytes through secondary transduction: delusions and solutions. Ramkisoensing AA, De Vries AA, Schalij MJ, Atsma DE, Pijnappels DA
Cardiomyogenic differentiation of stem cells can be accomplished by coculture with cardiomyocytes (CMCs). To facilitate their identification, stem cells are often labeled through viral transduction with a fluorescent protein. A second marker to distinguish stem cell-derived CMCs from native CMCs is rarely used. This study aimed to investigate the occurrence of secondary transduction of unlabeled neonatal rat (nr) CMCs after coculture with human cells that had been transduced 0, 7, or 14 days ear... Abstract
Cited 17 times since 2012 (1.5 per year) source: EuropePMC
American heart journal, Volume 164, Issue 5, 16 3 2012, Pages 771-778 Intramyocardial injection of bone marrow mononuclear cells in chronic myocardial ischemia patients after previous placebo injection improves myocardial perfusion and anginal symptoms: an intra-patient comparison. Rodrigo SF, van Ramshorst J, Beeres SL, Al Younis I, Dibbets-Schneider P, de Roos A, Fibbe WE, Zwaginga JJ, Schalij MJ, Bax JJ, Atsma DE
Background: We recently demonstrated in a randomized, double-blind, placebo-controlled trial that intramyocardial bone marrow cell (BMC) injection is associated with improvements in myocardial perfusion and anginal symptoms in chronic myocardial ischemia patients. In the present study the results of the crossover phase of this trial, in which patients previously treated with placebo received autologous BMC injections are reported. This allows a unique intra-patient comparison on the effect of BM... Abstract
Cited 12 times since 2012 (1 per year) source: EuropePMC
Cardiovascular research, Volume 97, Issue 1, 12 2 2012, Pages 171-181 Similar arrhythmicity in hypertrophic and fibrotic cardiac cultures caused by distinct substrate-specific mechanisms. Askar SF, Bingen BO, Schalij MJ, Swildens J, Atsma DE, Schutte CI, de Vries AA, Zeppenfeld K, Ypey DL, Pijnappels DA
Aims: Cardiac hypertrophy and fibrosis are associated with potentially lethal arrhythmias. As these substrates often occur simultaneously in one patient, distinguishing between pro-arrhythmic mechanisms is difficult. This hampers understanding of underlying pro-arrhythmic mechanisms and optimal treatment. This study investigates and compares arrhythmogeneity and underlying pro-arrhythmic mechanisms of either cardiac hypertrophy or fibrosis in in vitro models. Methods and results: Fibrosis was mi... Abstract
Cited 26 times since 2012 (2.2 per year) source: EuropePMC
Journal of cellular and molecular medicine, Volume 16, Issue 7, 1 1 2012, Pages 1508-1521 Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. den Haan MC, Grauss RW, Smits AM, Winter EM, van Tuyn J, Pijnappels DA, Steendijk P, Gittenberger-De Groot AC, van der Laarse A, Fibbe WE, de Vries AA, Schalij MJ, Doevendans PA, Goumans MJ, Atsma DE
We previously showed that human cardiomyocyte progenitor cells (hCMPCs) injected after myocardial infarction (MI) had differentiated into cardiomyocytes in vivo 3 months after MI. Here, we investigated the short-term (2 weeks) effects of hCMPCs on the infarcted mouse myocardium. MI was induced in immunocompromised (NOD/scid) mice, immediately followed by intramyocardial injection of hCMPCs labelled with enhanced green fluorescent protein (hCMPC group) or vehicle only (control group). Sham-operat... Abstract
Cited 17 times since 2012 (1.4 per year) source: EuropePMC
Stem cells (Dayton, Ohio), Volume 30, Issue 6, 1 1 2012, Pages 1236-1245 Gap junctional coupling with cardiomyocytes is necessary but not sufficient for cardiomyogenic differentiation of cocultured human mesenchymal stem cells. Ramkisoensing AA, Pijnappels DA, Swildens J, Goumans MJ, Fibbe WE, Schalij MJ, de Vries AA, Atsma DE
Gap junctional coupling is important for functional integration of transplanted cells with host myocardium. However, the role of gap junctions in cardiomyogenic differentiation of transplanted cells has not been directly investigated. The objective of this work is to study the role of connexin43 (Cx43) in cardiomyogenic differentiation of human mesenchymal stem cells (hMSCs). Knockdown of Cx43 gene expression (Cx43↓) was established in naturally Cx43-rich fetal amniotic membrane (AM) hMSCs, whil... Abstract
Cited 26 times since 2012 (2.2 per year) source: EuropePMC
PloS one, Volume 7, Issue 5, 4 1 2012, Pages e36115 Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. Yiu KH, Atsma DE, Delgado V, Ng AC, Witkowski TG, Ewe SH, Auger D, Holman ER, van Mil AM, Breuning MH, Tse HF, Bax JJ, Schalij MJ, Marsan NA
Background: To evaluate the presence of myocardial structural alterations and subtle myocardial dysfunction during familial screening in asymptomatic mutation carriers without hypertrophic cardiomyopathy (HCM) phenotype. Methods and findings: Sixteen HCM families with pathogenic mutation were studied and 46 patients with phenotype expression (Mut+/Phen+) and 47 patients without phenotype expression (Mut+/Phen-) were observed. Twenty-five control subjects, matched with the Mut+/Phen- group, were... Abstract
Cited 21 times since 2012 (1.7 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 20, Issue 4, 1 1 2012, Pages 167-175 Treatment options in end-stage heart failure: where to go from here? Haeck ML, Hoogslag GE, Rodrigo SF, Atsma DE, Klautz RJ, van der Wall EE, Schalij MJ, Verwey HF
Chronic heart failure is a major healthcare problem associated with high morbidity and mortality. Despite significant progress in treatment strategies, the prognosis of heart failure patients remains poor. The golden standard treatment for heart failure is heart transplantation after failure of medical therapy, surgery and/or cardiac resynchronisation therapy. In order to improve patients' outcome and quality of life, new emerging treatment modalities are currently being investigated, inclu... Abstract
Cited 18 times since 2012 (1.5 per year) source: EuropePMC
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Volume 7, Issue 9, 1 1 2012, Pages 1021-1029 Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. Boden H, van der Hoeven BL, Liem SS, Atary JZ, Cannegieter SC, Atsma DE, Bootsma M, Jukema JW, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ
Aims: To evaluate the clinical outcomes of sirolimus-eluting stent (SES) versus bare metal stent (BMS) implantation in patients with ST-segment elevation myocardial infarction (STEMI) at long-term follow-up. Methods and results: After five years, 310 STEMI patients randomly assigned to implantation of either SES or BMS, were compared. Survival rates were comparable between groups (SES 94.3% vs. BMS 92.8%, p=0.57), as were the rates of reinfarction (10.6% vs. 13.7%, p=0.40), freedom of death/re-M... Abstract
Cited 33 times since 2011 (2.7 per year) source: EuropePMC
Cardiovascular research, Volume 93, Issue 3, 22 4 2011, Pages 434-444 Connexin43 silencing in myofibroblasts prevents arrhythmias in myocardial cultures: role of maximal diastolic potential. Askar SF, Bingen BO, Swildens J, Ypey DL, van der Laarse A, Atsma DE, Zeppenfeld K, Schalij MJ, de Vries AA, Pijnappels DA
Aims: Arrhythmogenesis in cardiac fibrosis remains incompletely understood. Therefore, this study aims to investigate how heterocellular coupling between cardiomyocytes (CMCs) and myofibroblasts (MFBs) affects arrhythmogeneity of fibrotic myocardial cultures. Potentially, this may lead to the identification of novel anti-arrhythmic strategies. Methods and results: Co-cultures of neonatal rat CMCs and MFBs in a 1:1 ratio were used as a model of cardiac fibrosis, with purified CMC cultures as cont... Abstract
Cited 21 times since 2011 (1.7 per year) source: EuropePMC
Journal of cellular and molecular medicine, Volume 15, Issue 12, 1 1 2011, Pages 2675-2683 Epithelial-to-mesenchymal transformation alters electrical conductivity of human epicardial cells. Bax NA, Pijnappels DA, van Oorschot AA, Winter EM, de Vries AA, van Tuyn J, Braun J, Maas S, Schalij MJ, Atsma DE, Goumans MJ, Gittenberger-de Groot AC
The myocardium of the developing heart tube is covered by epicardium. These epicardial cells undergo a process of epithelial-to-mesenchymal transformation (EMT) and develop into epicardium-derived cells (EPDCs). The ingrowing EPDCs differentiate into several celltypes of which the cardiac fibroblasts form the main group. Disturbance of EMT of the epicardium leads to serious hypoplasia of the myocardium, abnormal coronary artery differentiation and Purkinje fibre paucity. Interestingly, the elect... Abstract
Cited 1 times since 2011 (0.1 per year) source: EuropePMC
Current pharmaceutical design, Volume 17, Issue 30, 1 1 2011, Pages 3308-3327 Cell therapy for the treatment of chronic ischemic heart disease. Rodrigo SF, Ramshorst Jv, Beeres SL, Bax JJ, Schalij MJ, Atsma DE
Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patients with chronic ischemic heart disease. After initial clinical studies have provided evidence for safety of cell administration, larger randomized trials demonstrated variable effect... Abstract
Cited 48 times since 2011 (3.8 per year) source: EuropePMC
PloS one, Volume 6, Issue 9, 9 2 2011, Pages e24164 Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. Ramkisoensing AA, Pijnappels DA, Askar SF, Passier R, Swildens J, Goumans MJ, Schutte CI, de Vries AA, Scherjon S, Mummery CL, Schalij MJ, Atsma DE
Mesenchymal stem cells (MSCs) show unexplained differences in differentiation potential. In this study, differentiation of human (h) MSCs derived from embryonic, fetal and adult sources toward cardiomyocytes, endothelial and smooth muscle cells was investigated. Labeled hMSCs derived from embryonic stem cells (hESC-MSCs), fetal umbilical cord, bone marrow, amniotic membrane and adult bone marrow and adipose tissue were co-cultured with neonatal rat cardiomyocytes (nrCMCs) or cardiac fibroblasts... Abstract
Cited 133 times since 2011 (10.2 per year) source: EuropePMC
Circulation, Volume 123, Issue 23, 23 4 2011, Pages 2690-2700 Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M, Bhuiyan ZA, Wiesfeld AC, Volders PG, van Langen IM, Atsma DE, Dooijes D, van den Wijngaard A, Houweling AC, Jongbloed JD, Jordaens L, Cramer MJ, Doevendans PA, de Bakker JM, Wilde AA, van Tintelen JP, Hauer RN
Background: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an autosomal dominant inherited disease with incomplete penetrance and variable expression. Causative mutations in genes encoding 5 desmosomal proteins are found in ≈50% of ARVD/C index patients. Previous genotype-phenotype relation studies involved mainly overt ARVD/C index patients, so follow-up data on relatives are scarce. Methods and results: One hundred forty-nine ARVD/C index patients (111 male patients; age... Abstract
Cited 38 times since 2011 (2.9 per year) source: EuropePMC
European heart journal, Volume 32, Issue 9, 1 1 2011, Pages 1161-1170 Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Christiaans I, Birnie E, Bonsel GJ, Mannens MM, Michels M, Majoor-Krakauer D, Dooijes D, van Tintelen JP, van den Berg MP, Volders PG, Arens YH, van den Wijngaard A, Atsma DE, Helderman-van den Enden AT, Houweling AC, de Boer K, van der Smagt JJ, Hauer RN, Marcelis CL, Timmermans J, van Langen IM, Wilde AA
Aims: We investigated the presence of a clinical diagnosis of hypertrophic cardiomyopathy (HCM), risk factors for sudden cardiac death (SCD), and cardiac events during follow-up in predictively tested-not known to have a clinical diagnosis of HCM before the DNA test-carriers of a sarcomeric gene mutation and associations with age and gender to determine the best cardiological screening strategy. Methods and results: One hundred and thirty-six (30%) of 446 mutation carriers were diagnosed with HC... Abstract
Cited 26 times since 2011 (1.9 per year) source: EuropePMC
Cardiovascular research, Volume 90, Issue 2, 13 2 2011, Pages 295-304 Antiproliferative treatment of myofibroblasts prevents arrhythmias in vitro by limiting myofibroblast-induced depolarization. Askar SF, Ramkisoensing AA, Schalij MJ, Bingen BO, Swildens J, van der Laarse A, Atsma DE, de Vries AA, Ypey DL, Pijnappels DA
Aims: Cardiac fibrosis is associated with increased incidence of cardiac arrhythmias, but the underlying proarrhythmic mechanisms remain incompletely understood and antiarrhythmic therapies are still suboptimal. This study tests the hypothesis that myofibroblast (MFB) proliferation leads to tachyarrhythmias by altering the excitability of cardiomyocytes (CMCs) and that inhibition of MFB proliferation would thus lower the incidence of such arrhythmias. Methods and results: Endogenous MFBs in neon... Abstract
Cited 15 times since 2011 (1.1 per year) source: EuropePMC
Journal of cardiovascular translational research, Volume 4, Issue 2, 7 1 2011, Pages 182-191 Bone marrow cell injection for chronic myocardial ischemia: the past and the future. van Ramshorst J, Rodrigo SF, Schalij MJ, Beeres SL, Bax JJ, Atsma DE
Intramyocardial bone marrow cell injection is currently being investigated as a new therapeutic option for the treatment of chronic myocardial ischemia. Experimental studies and early phase clinical trials established a favorable safety profile of this approach and suggested that bone marrow cell injection was associated with clinical and functional improvements. Recently, a randomized, double-blind, placebo-controlled trial demonstrated that intramyocardial bone marrow cell injection was associ... Abstract